Drugs Made In America Acquisition (NASDAQ:DMAA – Get Free Report) issued its quarterly earnings data on Monday. The company reported $0.05 earnings per share for the quarter, FiscalAI reports.
Drugs Made In America Acquisition Price Performance
Shares of NASDAQ:DMAA opened at $10.90 on Wednesday. Drugs Made In America Acquisition has a 52-week low of $10.32 and a 52-week high of $10.91. The stock has a 50 day moving average price of $10.87 and a 200-day moving average price of $10.66.
Institutional Investors Weigh In On Drugs Made In America Acquisition
Hedge funds have recently made changes to their positions in the company. Glazer Capital LLC purchased a new stake in Drugs Made In America Acquisition in the third quarter worth $9,279,000. First Trust Capital Management L.P. purchased a new position in Drugs Made In America Acquisition during the third quarter valued at $8,557,000. Finally, Sona Asset Management US LLC purchased a new position in Drugs Made In America Acquisition during the first quarter valued at $1,706,000.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings restated a “sell (d)” rating on shares of Drugs Made In America Acquisition in a report on Wednesday, August 26th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the company has a consensus rating of “Sell”.
Read Our Latest Analysis on Drugs Made In America Acquisition
About Drugs Made In America Acquisition
Drugs Made In America Acquisition Corp. is a special purpose acquisition company formed to pursue a merger, asset acquisition, or similar business combination. It does not operate a pharmaceutical business or manufacture drugs itself. The company’s stated focus was on identifying a business in the pharmaceutical industry, particularly one connected with drug manufacturing in the United States. Its activities were centered on seeking a suitable acquisition or merger candidate.
Further Reading
- Five stocks we like better than Drugs Made In America Acquisition
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
Receive News & Ratings for Drugs Made In America Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Drugs Made In America Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
